用于质子治疗在线射程验证的碘化造影剂活化测量
Activation measurements of an iodinated contrast media for online range verification in proton therapy
AI总结：
本研究针对质子治疗在线射程验证需求，开展碘化造影剂的质子活化原理验证实验，证实碘的活化信号可被有效识别，为临床质子射程监测提供新途径。
摘要：
此前已有研究提出将造影剂用作提升布拉格峰附近活化程度的新方法，旨在提高体内质子射程监测的质量。在近期工作中，我们已证实$^{127}$I可用于在线验证，这得益于它较高的反应截面（10 MeV时为200 mbarn）以及$^{127m}$Xe较低的生成能阈。该基于能谱的方法依靠识别两条特定的延迟γ射线（能量为124.6 keV和172.5 keV），可通过单光子发射计算机断层扫描（SPECT）进行分析。本研究开展了一项原理验证研究，探究商用放射科碘化造影剂（ICM）中的质子活化情况。我们在6-10 MeV的不同质子能量下开展了五次测量，该能量范围对应临床质子射程的最后几毫米。研究使用四台LaBr$_3$(Ce)闪烁体探测器测量了ICM中的活化程度，将碘的贡献与溶剂的活化作用分离开来，所得结果与此前报道的数据高度吻合。这些结果证明了该技术的潜力，为后续在临床相关场景中开展测试奠定了基础。
英文摘要：
The use of contrast agents has previously been proposed as a novel method to increase the activation close to the Bragg peak, aiming to improve the quality of proton range monitoring in vivo. In a recent work, we demonstrated the feasibility of $^{127}$I for online verification, thanks to its high cross-section (200 mbarn at 10 MeV) and low energy production threshold for $^{127m}$Xe. The spectroscopy-based method relies on identifying two specific delayed $γ$ lines (at 124.6 and 172.5 keV), which can be analyzed via single-photon emission computed tomography (SPECT). In this work, we present a proof-of-principle study to investigate proton activation in a commercial iodinated contrast media (ICM) for radiology. Five measurements were conducted at different proton energies (6-10 MeV), equivalent to the last millimeters of clinical proton range. Activation in the ICM was measured with four LaBr$_3$(Ce) scintillators. The contribution from iodine was separated from the activation of the solvent, yielding excellent agreement with previously reported data. These results demonstrate the potential of this technique and pave the way for further testing in clinically relevant scenarios.
机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。
